Endocrine treatment of prostatic cancer.
作者信息
Williams G
出版信息
J R Soc Med. 1985 Oct;78(10):797-9. doi: 10.1177/014107688507801001.
Abstract
摘要
相似文献
1
Endocrine treatment of prostatic cancer.前列腺癌的内分泌治疗
J R Soc Med. 1985 Oct;78(10):797-9. doi: 10.1177/014107688507801001.
2
[Hormones and antihormones, cancer of the breast and prostate, escape and treatment].
Ann Endocrinol (Paris). 2003 Oct;64(4):350-1.
3
Luteinizing hormone-releasing hormone (LH-RH) analogs in treatment of prostatic cancer. Clinical perspective.
Urology. 1986 Jan;27(1 Suppl):9-15. doi: 10.1016/s0090-4295(86)80004-8.
4
Endocrine factors in the treatment of prostatic cancer.前列腺癌治疗中的内分泌因素。
Prog Clin Biol Res. 1985;185A:51-72.
5
What is new in endocrine therapy of prostatic cancer?前列腺癌内分泌治疗有哪些新进展？
Prog Clin Biol Res. 1990;357:45-52.
6
Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments.前列腺癌的药物治疗，重点是激素治疗。
Expert Opin Pharmacother. 2006 Sep;7(13):1685-99. doi: 10.1517/14656566.7.13.1685.
7
Current topics and perspectives in the treatment of endocrine-related cancers.
Int J Clin Oncol. 2008 Oct;13(5):377-9. doi: 10.1007/s10147-008-0832-9. Epub 2008 Oct 23.
8
New forms and future perspectives in endocrine treatment of prostatic carcinoma.
Prog Clin Biol Res. 1984;153:529-45.
9
Special issue on steroids and cancer. Preface.类固醇与癌症特刊。前言。
J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):67. doi: 10.1016/j.jsbmb.2012.05.009.
10
[GnRH antagonists--a new therapy option for advanced prostate cancer].[促性腺激素释放激素拮抗剂——晚期前列腺癌的一种新治疗选择]
Aktuelle Urol. 2009 May;40(3):159-63. doi: 10.1055/s-0028-1098882. Epub 2009 Apr 27.
引用本文的文献
1
A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).新型非甾体类纯抗雄激素药物康士得（ICI 176,334）外周选择性的一种可能解释。
Br J Cancer. 1989 Nov;60(5):664-8. doi: 10.1038/bjc.1989.336.
本文引用的文献
1
2
Anti-estrogens in the treatment of prostatic cancer.抗雌激素药物在前列腺癌治疗中的应用
Acta Urol Belg. 1980 Jan;48(1):106-9.
3
Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer.
J Urol. 1982 Mar;127(3):466-71. doi: 10.1016/s0022-5347(17)53868-9.
4
Medical castration with megestrol acetate and minidose of diethylstilbestrol.醋酸甲地孕酮与小剂量己烯雌酚的药物去势治疗
Urology. 1981 Apr;17(4 Suppl):27-33.
5
The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.用一种强效促黄体生成激素释放激素类似物治疗转移性前列腺癌。
J Urol. 1983 Jun;129(6):1149-52. doi: 10.1016/s0022-5347(17)52615-4.
6
Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.用于前列腺癌的可生物降解聚合物促黄体生成素释放激素类似物：一种新型肽递送系统的应用
Br Med J (Clin Res Ed). 1984 Dec 8;289(6458):1580-1. doi: 10.1136/bmj.289.6458.1580.
7
Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.长期使用促黄体生成素释放激素治疗前列腺癌未能抑制血清促黄体生成素和睾酮。
Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):468-9. doi: 10.1136/bmj.289.6443.468.
8
Steroid receptors and hormone responsiveness of human prostatic carcinoma.人前列腺癌的类固醇受体与激素反应性
Prostate. 1982;3(5):475-82. doi: 10.1002/pros.2990030506.
9
Estrogen receptors and clinical correlations with human prostatic disease.雌激素受体及其与人类前列腺疾病的临床关联。
Urology. 1982 Apr;19(4):399-403. doi: 10.1016/0090-4295(82)90197-2.
10
Analysis of androgen receptors in the human prostate by isoelectric focussing in polyacrylamide gel.
J Steroid Biochem. 1981 Dec;14(12):1261-7. doi: 10.1016/0022-4731(81)90330-7.
Zotero 插件